RxDoctor Payments Data

Mary Glenn Shuart

Psychiatric/Mental Health · Doylestown, PANPI 1407904030

Payments from drug & device makers

$2,552in general payments, 2019–2025

Across 132 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$463
  • Lundbeck LLC$311
  • Alkermes, Inc.$297
  • AbbVie$266
  • Otsuka America Pharmaceutical, Inc.$253
  • Corium, LLC$186
  • plus $775 from 14 others

What the payments were for

  • Food & beverage$2,50398%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,552 in reported general payments places this provider in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$55,732
Medicare patients
153
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$101,323
VraylarCariprazine Hcl40$56,032
Invega SustennaPaliperidone Palmitate14$24,789
ProzacFluoxetine Hcl22$11,654
Lurasidone Hcl52$11,038
FetzimaLevomilnacipran Hcl13$6,838
Clozapine130$6,374
Aripiprazole165$5,969
Venlafaxine Hcl ErVenlafaxine Hcl92$4,833
Fluvoxamine Maleate ErFluvoxamine Maleate12$4,034
Ziprasidone Hcl39$2,685
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine72$2,007
Quetiapine Fumarate108$1,992
Olanzapine171$1,530
Lorazepam165$1,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$266$62,87053 claims
Almatica Pharma LLCSertraline Hcl$19$577119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →